FMR LLC sells 284,860 Beam Therapeutics shares

FMR LLC, a ten percent owner of Beam Therapeutics Inc., reported indirect open-market sales of Beam common stock through F-Prime Capital Partners Healthcare Fund V LP.

Rhea-AI Filing Summary

FMR LLC, a ten percent owner of Beam Therapeutics Inc., reported indirect open-market sales of Beam common stock through F-Prime Capital Partners Healthcare Fund V LP.

The entity sold 33,372 shares on June 25, 2026 at a weighted average price of $35.12 per share, and 251,488 shares on June 26, 2026 at a weighted average price of $35.26 per share, for total reported sales of 284,860 shares. After these transactions, one reported indirect holding shows 854,583 shares remaining for the F-Prime Capital Partners Healthcare Fund V LP position. Additional indirect holdings include 841,231 shares held by persons and entities whose shares are subject to reporting by FMR LLC and 14 shares held by FMR Capital, Inc.

Insights

Equity ownership analyst

Large shareholder executes sizable open-market sales but retains a substantial position.

FMR LLC, as a ten percent owner, reported net open-market sales of 284,860 shares of Beam Therapeutics common stock via entities it reports, primarily F-Prime Capital Partners Healthcare Fund V LP. The transactions were straightforward sales with prices in the mid-$30s per share.

Following these sales, F-Prime Capital Partners Healthcare Fund V LP still reports 854,583 shares indirectly owned, and other indirect holdings remain in related entities. With no derivative exercises or 10b5-1 trading plan disclosures in the provided data, this filing mainly updates the market on a notable but not thesis-changing reduction in a large holder’s position.

Insider Trade Summary

Net Seller: 284,860 shares

Net Sell 4 txns

Insider FMR LLC

Role 10% Owner

Sold 284,860 shs ($10.04M)

Type	Security	Shares	Price	Value
Sale	Common Stock	251,488	$35.26	$8.87M
Sale	Common Stock	33,372	$35.12	$1.17M
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 854,583 shares (Indirect, F-Prime Capital Partners Healthcare Fund V LP); Common Stock — 14 shares (Indirect, FMR Capital, Inc.); Common Stock — 841,231 shares (Indirect, Shares held by persons and entities whose shares are subject to reporting by the undersigned.)

Footnotes (2)

1. F1. The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $35.00 to $35.39. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.
2. F2. The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $35.00 to $35.88. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.

Key Figures

Shares sold June 25, 2026: 33,372 shares Shares sold June 26, 2026: 251,488 shares Total shares sold: 284,860 shares +4 more

7 metrics

Shares sold June 25, 2026 33,372 shares Open-market sale at weighted average $35.12 per share

Shares sold June 26, 2026 251,488 shares Open-market sale at weighted average $35.26 per share

Total shares sold 284,860 shares Net reported common stock sales across both transactions

Holding after June 26 sale 854,583 shares Indirect common stock position of F-Prime Capital Partners Healthcare Fund V LP

Additional reported holdings 841,231 shares Indirect holdings by persons and entities subject to FMR LLC reporting

Small indirect holding 14 shares Indirectly held through FMR Capital, Inc.

Net buy/sell direction Net sale of 284,860 shares transactionSummary netBuySellShares and netBuySellDirection

Key Terms

open-market sale, indirect ownership, ten percent owner, weighted average price, +1 more

5 terms

open-market sale financial

"transaction_action is described as an open-market sale of common stock"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

indirect ownership financial

"direct_or_indirect is coded as I, indicating indirect ownership of the shares"

ten percent owner financial

"FMR LLC is marked as a ten percent owner of Beam Therapeutics"

weighted average price financial

"footnotes state the price is the weighted average of multiple trades"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Common Stock financial

"all reported transactions involve Beam Therapeutics Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did FMR LLC report for Beam Therapeutics (BEAM)?

FMR LLC reported indirect open-market sales of Beam Therapeutics common stock totaling 284,860 shares. These sales were executed through F-Prime Capital Partners Healthcare Fund V LP over two days at weighted average prices in the mid-$35 range per share.

How many Beam Therapeutics (BEAM) shares did FMR LLC’s affiliated fund sell and at what prices?

F-Prime Capital Partners Healthcare Fund V LP sold 33,372 Beam shares on June 25, 2026 at a weighted average price of $35.12, and 251,488 shares on June 26, 2026 at a weighted average price of $35.26, for total reported sales of 284,860 shares.

How many Beam Therapeutics (BEAM) shares does F-Prime Capital Partners Healthcare Fund V LP hold after the sales?

After the reported open-market sales, F-Prime Capital Partners Healthcare Fund V LP holds 854,583 Beam Therapeutics common shares indirectly. This figure reflects the position following the June 26, 2026 transaction disclosed in the Form 4 insider filing data.

Does FMR LLC still have other indirect holdings of Beam Therapeutics (BEAM) stock?

Yes. In addition to 854,583 shares indirectly held through F-Prime Capital Partners Healthcare Fund V LP, FMR LLC reports 841,231 Beam shares held by persons and entities subject to its reporting, and 14 shares held indirectly through FMR Capital, Inc., as of June 25, 2026.

Were the Beam Therapeutics (BEAM) insider transactions by FMR LLC open-market sales?

The Form 4 characterizes both transactions with code “S” as open-market or private sales. Transaction metadata explicitly describes the actions as open-market sales of Beam Therapeutics common stock, with prices reported as weighted averages for multiple individual trades.

Did FMR LLC exercise any options or derivatives in this Beam Therapeutics (BEAM) filing?

No derivative exercises are shown in the provided data. The derivativeSummary section is empty, and the transactionSummary reports zero derivative exercises, indicating the filing only reflects common stock sales and holding entries, not option or warrant activity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 02:17 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FMR LLC

(Last) (First) (Middle)

245 SUMMER STREET

(Street)

BOSTON MASSACHUSETTS 02210

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beam Therapeutics Inc. [ BEAM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)	X	Other (specify below)
			See Remark 1

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/25/2026		S		33,372	D	$35.12(1)	1,106,071	I	F-Prime Capital Partners Healthcare Fund V LP
Common Stock	06/26/2026		S		251,488	D	$35.26(2)	854,583	I	F-Prime Capital Partners Healthcare Fund V LP
Common Stock								14	I	FMR Capital, Inc.
Common Stock								841,231	I	Shares held by persons and entities whose shares are subject to reporting by the undersigned.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $35.00 to $35.39. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.

2. The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $35.00 to $35.88. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.

Remarks:

Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: The general partner of F-Prime Capital Partners Healthcare Fund V LP is F-Prime Capital Partners Healthcare Advisors Fund V LP (FPCPHA). FPCPHA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager. FMR Capital, Inc. is a wholly owned subsidiary of FMR LLC.

	/s/ Stephanie J. Brown, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)